Back to News
Market Impact: 0.3
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookProduct Launches
Compass Pathways expects to complete the rolling New Drug Application submission for COMP360, its synthetic psilocybin treatment for treatment-resistant depression, in Q4. The company continues to target a potential commercial launch in H1 2027, representing a positive regulatory and commercialization milestone but with material approval and execution risk remaining.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CMPS0.55
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- A ‘geologic freak’ called the Smackover may end America’s lithium dependence on China, and Big Oil is already there
- Investing in Prediction Markets Will Pay Off, DraftKings CEO Says
- Where's the growth? Legacy automakers face a tougher 2027 as costs rise, market tightens
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction